Drug Type Small molecule drug |
Synonyms VVD 699, VVD699 |
Target |
Action inhibitors |
Mechanism PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors), RAS inhibitors(RAS type GTPase family inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC25H30ClFN2O6S2 |
InChIKeyYWSLDFWCZLZVST-DRZNZDJGSA-N |
CAS Registry3055319-82-6 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Cancer | Preclinical | United States | 09 Oct 2025 |





